Role of pseudoexons and pseudointrons in human cancer

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Romano, Maurizio ^a   Buratti, Emanuele ^b   Baralle, Diana ^c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; 5 METHYLTETRAHYDROFOLATE HOMOCYSTEINE METHYLTRANSFERASE; ACETYL COENZYME A ACYLTRANSFERASE; ACETYLCHOLINESTERASE; ALDEHYDE DEHYDROGENASE; ANTISENSE OLIGONUCLEOTIDE; ATM PROTEIN; BETA GLUCURONIDASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CD40 LIGAND; CYTOCHROME P450; ENOYL COENZYME A HYDRATASE; ESTROGEN RECEPTOR ALPHA; FIBRONECTIN; G PROTEIN COUPLED RECEPTOR; GROWTH HORMONE RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; LACTADHERIN; MERLIN; METHYLCROTONOYL COENZYME A CARBOXYLASE; NEUROFIBROMIN; ORNITHINE CARBAMOYLTRANSFERASE; ORNITHINE OXOACID AMINOTRANSFERASE; PHOSPHOMANNOMUTASE; PROTEIN MSH2; PROTEOHEPARAN SULFATE; SERINE ARGININE RICH PROTEIN; THROMBOPOIETIN;

ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; APOPTOSIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CELL ADHESION; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENE REPRESSION; GENE STRUCTURE; GENETIC CODE; HUMAN; INTRON RETENTION; NEOPLASM; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PSEUDOEXON; PSEUDOGENE; PSEUDOINTRON; REVIEW; RNA PROCESSING; RNA SPLICING; SPLICING DEFECT;

EID: 84885457755     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/810572     Document Type: Review

References (190)

1. Chow L. T., Gelinas R. E., Broker T. R., Roberts R. J., An amazing sequence arrangement at the 5′ ends of adenovirus 2 messenger RNA. Cell 1977 12 1 1 8 2-s2.0-0017688583 (Pubitemid 8193727)
2. Berget S. M., Moore C., Sharp P. A., Spliced segments at the 5′ terminus of adenovirus 2 late mRNA. Proceedings of the National Academy of Sciences of the United States of America 1977 74 8 3171 3175 2-s2.0-0344622123 (Pubitemid 8180310)
3. Darnell J. E. Jr., Reflections on the history of pre-mRNA processing and highlights of current knowledge: a unified picture. RNA 2013 19 4 443 460 10.1261/rna.038596.113
4. Nilsen T. W., The spliceosome: the most complex macromolecular machine in the cell? Bioessays 2003 25 12 1147 1149 2-s2.0-0344198459 10.1002/bies.10394 (Pubitemid 37499313)
5. Will C. L., Lührmann R., Spliceosome structure and function. Cold Spring Harbor Perspectives in Biology 2011 3 7 2-s2.0-80455144530
6. Semlow D. R., Staley J. P., Staying on message: ensuring fidelity in pre-mRNA splicing. Trends in Biochemical Sciences 2012 37 7 263 273 2-s2.0-84860555213 10.1016/j.tibs.2012.04.001
7. Cartegni L., Chew S. L., Krainer A. R., Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nature Reviews Genetics 2002 3 4 285 298 2-s2.0-0036207384 10.1038/nrg775 (Pubitemid 34279797)
8. Hertel K. J., Combinatorial control of exon recognition. The Journal of Biological Chemistry 2008 283 3 1211 1215 2-s2.0-38349127601 10.1074/jbc.R700035200
9. Kornblihtt A. R., Schor I. E., Allo M., Dujardin G., Petrillo E., Munoz M. J., Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nature Reviews Molecular Cell Biology 2013 14 153 165
10. Chabot B., Directing alternative splicing: cast and scenarios. Trends in Genetics 1996 12 11 472 478 2-s2.0-0030279439 10.1016/0168-9525(96)10037-8 (Pubitemid 126335953)
11. Black D. L., Mechanisms of alternative pre-messenger RNA splicing. Annual Review of Biochemistry 2003 72 291 336 2-s2.0-0013394889 10.1146/annurev. biochem.72.121801.161720 (Pubitemid 36930448)
12. Wang Y., Xiao X., Zhang J., Choudhury R., Robertson A., Li K., Ma M., Burge C. B., Wang Z., A complex network of factors with overlapping affinities represses splicing through intronic elements. Nature Structural & Molecular Biology 2013 20 36 45
13. Huelga S. C., Vu A. Q., Arnold J. D., Liang T. Y., Liu P. P., Yan B. Y., Donohue J. P., Shiue L., Hoon S., Brenner S., Ares M. Jr, Yeo G. W., Integrative genome-wide analysis reveals cooperative regulation of alternative splicing by hnRNP proteins. Cell Reports 2012 1 2 167 178
14. Pandit S., Zhou Y., Shiue L., Coutinho-Mansfield G., Li H., Qiu J., Huang J., Yeo G. W., Ares M. Jr, Fu X. D., Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Molecular Cell 2013 50 223 235
15. Schaal T. D., Maniatis T., Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Molecular and Cellular Biology 1999 19 1 261 273 2-s2.0-0032947182 (Pubitemid 29018428)
16. Graveley B. R., Sorting out the complexity of SR protein functions. RNA 2000 6 9 1197 1211 2-s2.0-0033835333 10.1017/S1355838200000960
17. Martinez-Contreras R., Cloutier P., Shkreta L., Fisette J. F., Revil T., Chabot B., hnRNP proteins and splicing control. Advances in Experimental Medicine and Biology 2007 623 123 147 2-s2.0-42449152457
18. Hnilicová J., Staněk D., Where splicing joins chromatin. Nucleus 2011 2 3 182 188 2-s2.0-79960330571 10.4161/nucl.2.3.15876
19. Acuña L. I. G., Fiszbein A., Alló M., Schor I. E., Kornblihtt A. R., Connections between chromatin signatures and splicing. Wiley Interdisciplinary Reviews 2013 4 1 77 91 10.1002/wrna.1142
20. Dujardin G., Lafaille C., Petrillo E., Buggiano V., Gomez Acuna L. I., Fiszbein A., Godoy Herz M. A., Nieto Moreno N., Munoz M. J., Allo M., Schor I. E., Kornblihtt A. R., Transcriptional elongation and alternative splicing. Biochimica et Biophysica Acta 2013 1829 1 134 140 10.1016/j.bbagrm.2012.08.005
21. Buratti E., Baralle F. E., Influence of RNA secondary structure on the pre-mRNA splicing process. Molecular and Cellular Biology 2004 24 24 10505 10514 2-s2.0-10044274340 10.1128/MCB.24.24.10505-10514.2004 (Pubitemid 39603113)
22. Khanna A., Stamm S., Regulation of alternative splicing by short non-coding nuclear RNAs. RNA Biology 2010 7 4 480 485 2-s2.0-77957315563 10.4161/rna.7.4.12746
23. Luco R. F., Misteli T., More than a splicing code: integrating the role of RNA, chromatin and non-coding RNA in alternative splicing regulation. Current Opinion in Genetics and Development 2011 21 4 366 372 2-s2.0-79957543093 10.1016/j.gde.2011.03.004
24. Biamonti G., Caceres J. F., Cellular stress and RNA splicing. Trends in Biochemical Sciences 2009 34 3 146 153 2-s2.0-62849087517 10.1016/j.tibs.2008. 11.004
25. Kelemen O., Convertini P., Zhang Z., Wen Y., Shen M., Falaleeva M., Stamm S., Function of alternative splicing. Gene 2013 514 1 30
26. Johnson T. L., Vilardell J., Regulated pre-mRNA splicing: the ghostwriter of the eukaryotic genome. Biochimica et Biophysica Acta 2012 1819 6 538 545 2-s2.0-84860426217 10.1016/j.bbagrm.2011.12.011
27. Zheng S., Black D. L., Alternative pre-mRNA splicing in neurons: growing up and extending its reach. Trends in Genetics 2013 29 8 442 448 10.1016/j.tig.2013.04.003
28. Norris A. D., Calarco J. A., Emerging roles of alternative pre-mRNA splicing regulation in neuronal development and function. Frontiers in Neuroscience 2012 6 122 10.3389/fnins.2012.00122
29. Mattick J. S., The central role of RNA in human development and cognition. FEBS Letters 2011 585 11 1600 1616 2-s2.0-79957537160 10.1016/j.febslet.2011.05.001
30. Grabowski P., Alternative splicing takes shape during neuronal development. Current Opinion in Genetics and Development 2011 21 4 388 394 2-s2.0-79960903405 10.1016/j.gde.2011.03.005
31. Yap K., Makeyev E. V., Regulation of gene expression in mammalian nervous system through alternative pre-mRNA splicing coupled with RNA quality control mechanisms. Molecular and Cellular Neuroscience 2013 10.1016/j.mcn.2013.01.003
32. Montecucco A., Biamonti G., Pre-mRNA processing factors meet the DNA damage response. Frontiers in Genetics 2013 4 102
33. Melamed Z., Levy A., Ashwal-Fluss R., Lev-Maor G., Mekahel K., Atias N., Gilad S., Sharan R., Levy C., Kadener S., Ast G., Alternative splicing regulates biogenesis of miRNAs located across exon-intron junctions. Molecular Cell 2013 50 6 869 881 10.1016/j.molcel.2013.05.007
34. Skoko N., Baralle M., Tisminetzky S., Buratti E., InTRONs in biotech. Molecular Biotechnology 2011 48 3 290 297 2-s2.0-80054037647 10.1007/s12033-011-9390-x
35. Pan Q., Shai O., Lee L. J., Frey B. J., Blencowe B. J., Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics 2008 40 1413 1415 10.1038/ng.259
36. Buratti E., Baralle M., Baralle F. E., Defective splicing, disease and therapy: searching for master checkpoints in exon definition. Nucleic Acids Research 2006 34 12 3494 3510 2-s2.0-33746855164 10.1093/nar/gkl498
37. Krawczak M., Thomas N. S. T., Hundrieser B., Mort M., Wittig M., Hampe J., Cooper D. N., Single base-pair substitutions in exon-intron junctions of human genes: nature, distribution, and consequences for mRNA splicing. Human Mutation 2007 28 2 150 158 2-s2.0-33846934728 10.1002/humu.20400 (Pubitemid 46233312)
38. Dhir A., Buratti E., Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies: minireview. FEBS Journal 2010 277 4 841 855 2-s2.0-76149138842 10.1111/j.1742-4658.2009.07520.x
39. Baralle D., Lucassen A., Buratti E., Missed threads: the impact of pre-mRNA splicing defects on clinical practice. EMBO Reports 2009 10 8 810 816 2-s2.0-68249121529 10.1038/embor.2009.170
40. Eswaran J., Horvath A., Godbole S., RNA sequencing of cancer reveals novel splicing alterations. Scientific Reports 2013 3, article 1689
41. Venables J. P., Unbalanced alternative splicing and its significance in cancer. Bioessays 2006 28 4 378 386 2-s2.0-33645833000 10.1002/bies.20390
42. Relógio A., Ben-Dov C., Baum M., Ruggiu M., Gemund C., Benes V., Darnell R. B., Valcárcel J., Alternative splicing microarrays reveal functional expression of neuron-specific regulators in Hodgkin lymphoma cells. The Journal of Biological Chemistry 2005 280 6 4779 4784 2-s2.0-14244263334 10.1074/jbc.M411976200 (Pubitemid 40288649)
43. Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Gervais-Bird J., Madden R., Paquet É. R., Koh C., Venables J. P., Prinos P., Jilaveanu-Pelmus M., Wellinger R., Rancourt C., Chabot B., Elela S. A., Multiple alternative splicing markers for ovarian cancer. Cancer Research 2008 68 3 657 663 2-s2.0-38849179519 10.1158/0008-5472.CAN-07-2580 (Pubitemid 351206740)
44. Ghigna C., Valacca C., Biamonti G., Alternative splicing and tumor progression. Current Genomics 2008 9 8 556 570 2-s2.0-66049085709 10.2174/138920208786847971
45. David C. J., Manley J. L., Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes and Development 2010 24 21 2343 2364 2-s2.0-78049416081 10.1101/gad.1973010
46. Venables J. P., Aberrant and alternative splicing in cancer. Cancer Research 2004 64 21 7647 7654 2-s2.0-7444220147 10.1158/0008-5472.CAN-04-1910 (Pubitemid 39446889)
47. Kalni ņ a Z., Zayakin P., Sili ņ a K., Line A., Alterations of pre-mRNA splicing in cancer. Genes Chromosomes and Cancer 2005 42 4 342 357 2-s2.0-13944251747 10.1002/gcc.20156 (Pubitemid 40271278)
48. Srebrow A., Kornblihtt A. R., The connection between splicing and cancer. Journal of Cell Science 2006 119 13 2635 2641 2-s2.0-33746927884 10.1242/jcs.03053 (Pubitemid 44184000)
49. Pettigrew C. A., Brown M. A., Pre-mRNA splicing aberrations and cancer. Frontiers in Bioscience 2008 13 3 1090 1105 2-s2.0-38449111154 10.2741/2747 (Pubitemid 351594751)
50. Grosso A. R., Martins S., Carmo-Fonseca M., The emerging role of splicing factors in cancer. EMBO Reports 2008 9 11 1087 1093 2-s2.0-55549143293 10.1038/embor.2008.189
51. Ghigna C., Moroni M., Porta C., Riva S., Biamonti G., Altered expression of heterogeneous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Research 1998 58 24 5818 5824 2-s2.0-0032534232 (Pubitemid 29006424)
52. Zerbe L. K., Pino I., Pio R., Cosper P. F., Dwyer-Nield L. D., Meyer A. M., Port J. D., Montuenga L. M., Malkinson A. M., Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Molecular Carcinogenesis 2004 41 4 187 196 2-s2.0-9244221107 10.1002/mc.20053 (Pubitemid 39552706)
53. Karni R., De Stanchina E., Lowe S. W., Sinha R., Mu D., Krainer A. R., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology 2007 14 3 185 193 2-s2.0-33847630730 10.1038/nsmb1209 (Pubitemid 46355578)
54. Padgett R. A., New connections between splicing and human disease. Trends in Genetics 2012 28 4 147 154 2-s2.0-84858999890 10.1016/j.tig.2012.01.001
55. Fu Y., Huang B., Shi Z., Han J., Wang Y., Huangfu J., Wu W., SRSF1 and SRSF9 RNA binding proteins promote Wnt signalling-mediated tumorigenesis by enhancing beta-catenin biosynthesis. EMBO Molecular Medicine 2013 5 737 750
56. Hirschfeld M., Jaeger M., Buratti E., Stuani C., Grueneisen J., Gitsch G., Stickeler E., Expression of tumor-promoting Cyr61 is regulated by hTRA2- β 1 and acidosis. Human Molecular Genetics 2011 20 12 2356 2365 2-s2.0-79957475859 10.1093/hmg/ddr128
57. Boise L. H., Gonzalez-Garcia M., Postema C. E., Ding L., Lindsten T., Turka L. A., Mao X., Nunez G., Thompson C. B., bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993 74 4 597 608 2-s2.0-0027282044 10.1016/0092-8674(93)90508-N (Pubitemid 23259741)
58. Garneau D., Revil T., Fisette J. F., Chabot B., Heterogeneous nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of the apoptotic mediator Bcl-x. The Journal of Biological Chemistry 2005 280 24 22641 22650 2-s2.0-20744450092 10.1074/jbc.M501070200 (Pubitemid 40853168)
59. Massiello A., Roesser J. R., Chalfant C. E., SAP155 binds to ceramide-responsive RNA cis-element 1 and regulates the alternative 5′ splice site selection of Bcl-x pre-mRNA. The FASEB Journal 2006 20 10 1680 1682 2-s2.0-33749349897 10.1096/fj.05-5021fje (Pubitemid 44961982)
60. Cloutier P., Toutant J., Shkreta L., Goekjian S., Revil T., Chabot B., Antagonistic effects of the SRp30c protein and cryptic 5′ splice sites on the alternative splicing of the apoptotic regulator Bcl-x. The Journal of Biological Chemistry 2008 283 31 21315 21324 2-s2.0-52049094582 10.1074/jbc.M800353200
61. Revil T., Toutant J., Shkreta L., Garneau D., Cloutier P., Chabot B., Protein kinase C-dependent control of Bcl-x alternative splicing. Molecular and Cellular Biology 2007 27 24 8431 8441 2-s2.0-37149014737 10.1128/MCB.00565-07
62. Montes M., Cloutier A., Sánchez-Hernández N., Michelle L., Lemieux B., Blanchette M., Hernández-Munain C., Chabot B., Suñé C., TCERG1 regulates alternative splicing of the Bcl-x gene by modulating the rate of RNA polymerase II transcription. Molecular and Cellular Biology 2012 32 4 751 762 2-s2.0-84856774960 10.1128/MCB.06255-11
63. Michelle L., Cloutier A., Toutant J., Shkreta L., Thibault P., Durand M., Garneau D., Gendron D., Lapointe E., Couture S., Le Hir H., Klinck R., Elela S. A., Prinos P., Chabot B., Proteins associated with the exon junction complex also control the alternative splicing of apoptotic regulators. Molecular and Cellular Biology 2012 32 5 954 967 2-s2.0-84857184337 10.1128/MCB.06130-11
64. Stickeler E., Kittrell F., Medina D., Berget S. M., Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene 1999 18 24 3574 3582 2-s2.0-0033578006 10.1038/sj.onc.1202671 (Pubitemid 29322382)
65. Scorilas A., Kyriakopoulou L., Katsaros D., Diamandis E. P., Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: overexpression in aggressive ovarian cancer. British Journal of Cancer 2001 85 2 190 198 2-s2.0-0034944535 10.1054/bjoc.2001.1885 (Pubitemid 32695738)
66. Sun H., Chasin L. A., Multiple splicing defects in an intronic false exon. Molecular and Cellular Biology 2000 20 17 6414 6425 2-s2.0-0033846543 10.1128/MCB.20.17.6414-6425.2000 (Pubitemid 30650229)
67. Sironi M., Menozzi G., Riva L., Cagliani R., Comi G. P., Bresolin N., Giorda R., Pozzoli U., Silencer elements as possible inhibitors of pseudoexon splicing. Nucleic Acids Research 2004 32 5 1783 1791 2-s2.0-2642513654 10.1093/nar/gkh341 (Pubitemid 38832723)
68. Zhang X. H. F., Chasin L. A., Computational definition of sequence motifs governing constitutive exon splicing. Genes and Development 2004 18 11 1241 1250 2-s2.0-2642525438 10.1101/gad.1195304 (Pubitemid 38720592)
69. Fairbrother W. G., Chasin L. A., Human genomic sequences that inhibit splicing. Molecular and Cellular Biology 2000 20 18 6816 6825 2-s2.0-0033811608 10.1128/MCB.20.18.6816-6825.2000
70. Zhang X. H. F., Leslie C. S., Chasin L. A., Dichotomous splicing signals in exon flanks. Genome Research 2005 15 6 768 779 2-s2.0-22344439658 10.1101/gr.3217705 (Pubitemid 41003100)
71. Buratti E., Dhir A., Lewandowska M. A., Baralle F. E., RNA structure is a key regulatory element in pathology ATM and CFTR pseudoexon inclusion events. Nucleic Acids Research 2007 35 13 4369 4383 2-s2.0-34547850638 10.1093/nar/gkm447 (Pubitemid 47248459)
72. Dhir A., Buratti E., Van Santen M. A., Lührmann R., Baralle F. E., The intronic splicing code: multiple factors involved in ATM pseudoexon definition. The EMBO Journal 2010 29 4 749 760 2-s2.0-77149153689 10.1038/emboj.2009.397
73. Scheinin I., Myllykangas S., Borze I., Böhling T., Knuutila S., Saharinen J., CanGEM: mining gene copy number changes in cancer. Nucleic Acids Research 2008 36 1 D830 D835 2-s2.0-38549116682 10.1093/nar/gkm802 (Pubitemid 351149831)
74. Hu G. K., Madore S. J., Moldover B., Jatkoe T., Balaban D., Thomas J., Wang Y., Predicting splice variant from DNA chip expression data. Genome Research 2001 11 7 1237 1345 2-s2.0-0034924450 10.1101/gr.165501 (Pubitemid 32677298)
75. Fan W., Khalid N., Hallahan A. R., Olson J. M., Lue P. Z., A statistical method for predicting splice variants between two groups of samples using GeneChip expression array data. Theoretical Biology and Medical Modelling 2006 3, article 19 2-s2.0-33745976118 10.1186/1742-4682-3-19 (Pubitemid 44064146)
76. Raponi M., Buratti E., Llorian M., Stuani C., Smith C. W. J., Baralle D., Polypyrimidine tract binding protein regulates alternative splicing of an aberrant pseudoexon in NF1. FEBS Journal 2008 275 24 6101 6108 2-s2.0-56849094416 10.1111/j.1742-4658.2008.06734.x
77. Wagner E. J., Garcia-Blanco M. A., Minireview: polypyrimidine tract binding protein antagonizes exon definition. Molecular and Cellular Biology 2001 21 10 3281 3288 2-s2.0-0035038207 10.1128/MCB.21.10.3281-3288.2001 (Pubitemid 32381764)
78. Spier I., Horpaopan S., Vogt S., Uhlhaas S., Morak M., Stienen D., Draaken M., Ludwig M., Holinski-Feder E., Nöthen M. M., Hoffmann P., Aretz S., Deep intronic APC mutations explain a substantial proportion of patients with familial or early-onset adenomatous polyposis. Human Mutation 2012 33 7 1045 1050 2-s2.0-84859716767 10.1002/humu.22082
79. Nakamura K., Du L., Tunuguntla R., Fike F., Cavalieri S., Morio T., Mizutani S., Brusco A., Gatti R. A., Functional characterization and targeted correction of atm mutations identified in japanese patients with ataxia-telangiectasia. Human Mutation 2012 33 1 198 208 2-s2.0-84857486516 10.1002/humu.21632
80. Pagani F., Buratti E., Stuani C., Bendix R., Dörk T., Baralle F. E., A new type of mutation causes a splicing defect in ATM. Nature Genetics 2002 30 4 426 429 2-s2.0-0036544858 10.1038/ng858
81. McConville C. M., Stankovic T., Byrd P. J., McGuire G. M., Yao Q. Y., Lennox G. G., Taylor A. M. R., Mutations associated with variant phenotypes in ataxia-telangiectasia. American Journal of Human Genetics 1996 59 2 320 330 2-s2.0-0029819493 (Pubitemid 26266347)
82. Cavalieri S., Pozzi E., Gatti R. A., Brusco A., Deep-intronic ATM mutation detected by genomic resequencing and corrected in vitro by antisense morpholino oligonucleotide (AMO). European Journal of Human Genetics 2013 21 7 774 778 10.1038/ejhg.2012.266
83. Sorel N., Mayeur-Rousse C., Deverrière S., Roy L., Brottier-Mancini E., Guilhot F., Turhan A. G., Chomel J. C., Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia. Journal of Molecular Diagnostics 2010 12 4 520 524 2-s2.0-77954355373 10.2353/jmoldx.2010. 090218
84. Laudadio J., Deininger M. W. N., Mauro M. J., Druker B. J., Press R. D., An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. Journal of Molecular Diagnostics 2008 10 2 177 180 2-s2.0-41149136353 10.2353/jmoldx.2008.070128 (Pubitemid 351428400)
85. Quigley N. B., Henley D. C., Hubbard R. A., Laudadio J., Press R. D., ABL kinase domain pseudoexon insertion is not uncommon in BCR-ABL transcripts. Journal of Molecular Diagnostics 2008 10 5 475 476 2-s2.0-52249085600 10.2353/jmoldx.2008.080055
86. Balz V., Prisack H. B., Bier H., Bojar H., Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. Cancer Genetics and Cytogenetics 2002 138 2 120 127 2-s2.0-0037110201 10.1016/S0165-4608(02)00601-5 (Pubitemid 36020466)
87. Chen X., Truong T. T. N., Weaver J., Bove B. A., Cattie K., Armstrong B. A., Daly M. B., Godwin A. K., Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. Human Mutation 2006 27 5 427 435 2-s2.0-33646365369 10.1002/humu.20319 (Pubitemid 43673329)
88. Anczukow O., Buisson M., Leone M., Coutanson C., Lasset C., Calender A., Sinilnikova O. M., Mazoyer S., BRCA2 deep intronic mutation causing activation of a cryptic exon: opening toward a new preventive therapeutic strategy. Clinical Cancer Research 2012 18 4903 4909
89. Wang M., Dotzlaw H., Fuqua S. A. W., Murphy L. C., A point mutation in the human estrogen receptor gene is associated with the expression of an abnormal estrogen receptor mRNA containing a 69 novel nucleotide insertion. Breast Cancer Research and Treatment 1997 44 2 145 151 2-s2.0-0030949095 10.1023/A:1005753117205 (Pubitemid 27248463)
90. Clendenning M., Buchanan D. D., Walsh M. D., Nagler B., Rosty C., Thompson B., Spurdle A. B., Hopper J. L., Jenkins M. A., Young J. P., Mutation deep within an intron of MSH2 causes Lynch syndrome. Familial Cancer 2011 10 2 297 301 2-s2.0-79958144950 10.1007/s10689-011-9427-0
91. Fernández-Rodríguez J., Castellsagué J., Benito L., Benavente Y., Capellá G., Blanco I., Serra E., Lázaro C., A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism. Human Mutation 2011 32 7 705 709 2-s2.0-79959753868 10.1002/humu.21500
92. Pros E., Fernández-Rodríguez J., Canet B., Benito L., Sánchez A., Benavides A., Ramos F. J., López-Ariztegui M. A., Capellá G., Blanco I., Serra E., Lázaro C., Antisense therapeutics for neurofibromatosis type 1 caused by deep intronic mutations. Human Mutation 2009 30 3 454 462 2-s2.0-61649121051 10.1002/humu.20933
93. Raponi M., Upadhyaya M., Baralle D., Functional splicing assay shows a pathogenic intronic mutation in neurofibromatosis type 1 (NF1) due to intronic sequence exonization. Human mutation 2006 27 3 294 295 2-s2.0-33746602741
94. Pros E., Gómez C., Martín T., Fábregas P., Serra E., Lázaro C., Nature and mRNA effect of 282 different NF1 point mutations: focus on splicing alterations. Human mutation 2008 29 9 E173 E193 2-s2.0-61649123895 10.1002/humu.20826
95. Wimmer K., Roca X., Beiglböck H., Callens T., Etzler J., Rao A. R., Krainer A. R., Fonatsch C., Messiaen L., Extensive in silico analysis of NF1 splicing defects uncovers determinants for splicing outcome upon 5′ splice-site disruption. Human Mutation 2007 28 6 599 612 2-s2.0-34248338233 10.1002/humu.20493 (Pubitemid 46744290)
96. Perrin G., Morris M. A., Antonarakis S. E., Boltshauser E., Hutter P., Two novel mutations affecting mRNA splicing of the neurofibromatosis type 1 (NF1) gene. Human Mutation 1996 7 172 175 (Pubitemid 26088346)
97. Ars E., Serra E., Garcia J., Kruyer H., Gaona A., Lazaro C., Estivill X., Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1. Human Molecular Genetics 2000 9 2 237 247 (Pubitemid 30052747)
98. de Klein A., Riegman P. H. J., Bijlsma E. K., Heldoorn A., Muijtjens M., den Bakker M. A., Avezaat C. J. J., Zwarthoff E. C., A G→A transition creates a branch point sequence and activation of a cryptic exon, resulting in the hereditary disorder neurofibromatosis 2. Human Molecular Genetics 1998 7 3 393 398 2-s2.0-0031594471 10.1093/hmg/7.3.393 (Pubitemid 28120627)
99. Dehainault C., Michaux D., Pagès-Berhouet S., Caux-Moncoutier V., Doz F., Desjardins L., Couturier J., Parent P., Stoppa-Lyonnet D., Gauthier-Villars M., Houdayer C., A deep intronic mutation in the RB1 gene leads to intronic sequence exonisation. European Journal of Human Genetics 2007 15 4 473 477 2-s2.0-33947636652 10.1038/sj.ejhg.5201787 (Pubitemid 46487702)
100. Mayer K., Ballhausen W., Leistner W., Rott H. D., Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochimica et Biophysica Acta 2000 1502 3 495 507 2-s2.0-0034670066 10.1016/S0925-4439(00)00072-7
101. Masala M. V., Scapaticci S., Olivieri C., Pirodda C., Montesu M. A., Cuccuru M. A., Pruneddu S., Danesino C., Cerimele D., Epidemiology and clinical aspects of Werner's syndrome in North Sardinia: description of a cluster. European Journal of Dermatology 2007 17 3 213 216 (Pubitemid 46847783)
102. Friedrich K., Lee L., Leistritz D. F., Nürnberg G., Saha B., Hisama F. M., Eyman D. K., Lessel D., Nürnberg P., Li C., Garcia-F-Villalta M. J., Kets C. M., Schmidtke J., Cruz V. T., van den Akker P. C., Boak J., Peter D., Compoginis G., Cefle K., Ozturk S., López N., Wessel T., Poot M., Ippel P. F., Groff-Kellermann B., Hoehn H., Martin G. M., Kubisch C., Oshima J., WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. Human Genetics 2010 128 1 103 111 2-s2.0-77954025436 10.1007/s00439-010-0832-5
103. Flanagan S. E., Xie W., Caswell R., Damhuis A., Vianey-Saban C., Akcay T., Darendeliler F., Bas F., Guven A., Siklar Z., Ocal G., Berberoglu M., Murphy N., 'Sullivan M O., Green A., Clayton P. E., Banerjee I., Clayton P. T., Hussain K., Weedon M. N., Ellard S., Next-generation sequencing reveals deep intronic cryptic ABCC8 and HADH splicing founder mutations causing hyperinsulinism by pseudoexon activation. The American Journal of Human Genetics 2013 92 131 136
104. Milh M., Pop A., Kanhai W., Villeneuve N., Cano A., Struys E. A., Salomons G. S., Chabrol B., Jakobs C., Atypical pyridoxine-dependent epilepsy due to a pseudoexon in ALDH7A1. Molecular Genetics and Metabolism 2012 105 4 684 686 2-s2.0-84858704107 10.1016/j.ymgme.2012.01.011
105. Lee W. I., Torgerson T. R., Schumacher M. J., Yel L., Zhu Q., Ochs H. D., Molecular analysis of a large cohort of patients with the hyper immunoglobulin M (IgM) syndrome. Blood 2005 105 5 1881 1890 2-s2.0-14944385521 10.1182/blood-2003-12-4420 (Pubitemid 40731768)
106. den Hollander A. I., Koenekoop R. K., Yzer S., Lopez I., Arends M. L., Voesenek K. E., Zonneveld M. N., Strom T. M., Meitinger T., Brunner H. G., Hoyng C. B., van den Born L. I., Rohrschneider K., Cremers F. P., Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. American Journal of Human Genetics 2006 79 556 561 (Pubitemid 44384265)
107. Collin R. W., den Hollander A. I., van der Velde-Visser S. D., Bennicelli J., Bennett J., Cremers F. P., Antisense Oligonucleotide (AON)-based Therapy for Leber Congenital Amaurosis caused by a Frequent Mutation in CEP290. Molecular Therapy 2012 1, article e14
108. van den Hurk J. A. J. M., van de Pol D. J. R., Wissinger B., van Driel M. A., Hoefsloot L. H., de Wijs I. J., van den Born I., Heckenlively J. R., Brunner H. G., Zrenner E., Ropers H. H., Cremers F. P. M., Novel types of mutation in the choroideremia (CHM) gene: a full-length L1 insertion and an intronic mutation activating a cryptic exon. Human Genetics 2003 113 3 268 275 2-s2.0-0042566074 10.1007/s00439-003-0970-0 (Pubitemid 36992286)
109. Knebelmann B., Forestier L., Drouot L., Quinones S., Chuet C., Benessy F., Saus J., Antignac C., Splice-mediated insertion of an Alu sequence in the COL4A3 mRNA causing autosomal recessive Alport syndrome. Human Molecular Genetics 1995 4 4 675 679 2-s2.0-0028969936
110. Akawi N., Al-Gazali L., Ali B. R., Clinical and molecular analysis of UAE fibrochondrogenesis patients expands the phenotype and reveals two COL11A1 homozygous null mutations. Clinical Genetics 2012 82 147 156 2-s2.0-79960318343 10.1111/j.1399-0004.2011.01734.x
111. Varon R., Gooding R., Steglich C., Marns L., Tang H., Angelicheva D., Yong K. K., Ambrugger P., Reinhold A., Morar B., Baas F., Kwa M., Tournev I., Guerguelcheva V., Kremensky I., Lochmüller H., Müllner-Eidenböck A., Merlini L., Neumann L., Bürger J., Walter M., Swoboda K., Thomas P. K., von Moers A., Risch N., Kalaydjieva L., Partial deficiency of the C-terminal-domain phosphatase of RNA polymerase II is associated with congenital cataracts facial dysmorphism neuropathy syndrome. Nature Genetics 2003 35 2 185 189 2-s2.0-0141618451 10.1038/ng1243 (Pubitemid 37187639)
112. Rump A., Rösen-Wolff A., Gahr M., Seidenberg J., Roos C., Walter L., Günther V., Roesler J., A splice-supporting intronic mutation in the last bp position of a cryptic exon within intron 6 of the CYBB gene induces its incorporation into the mRNA causing chronic granulomatous disease (CGD). Gene 2006 371 2 174 181 2-s2.0-33645758306 10.1016/j.gene.2005.11.036
113. Noack D., Heyworth P. G., Newburger P. E., Cross A. R., An unusual intronic mutation in the CYBB gene giving rise to chronic granulomatous disease. Biochimica et Biophysica Acta 2001 1537 2 125 131 2-s2.0-0035964987 10.1016/S0925-4439(01)00065-5 (Pubitemid 32885614)
114. Hwang D. Y., Hung C. C., Riepe F. G., Auchus R. J., Kulle A. E., Holterhus P. M., Chao M. C., Kuo M. C., Hwang S. J., Chen H. C., CYP17A1 intron mutation causing cryptic splicing in 17 α -hydroxylase deficiency. PloS ONE 2011 6, article e25492 9 2-s2.0-80053164262 10.1371/journal.pone.0025492
115. Ikeda H., Matsubara Y., Mikami H., Kure S., Owada M., Gough T., Smooker P. M., Dobbs M., Dahl H. H. M., Cotton R. G. H., Narisawa K., Molecular analysis of dihydropteridine reductase deficiency: identification of two novel mutations in Japanese patients. Human Genetics 1997 100 5-6 637 642 2-s2.0-0031409535 10.1007/s004390050566 (Pubitemid 28072369)
116. van Kuilenburg A. B. P., Meijer J., Mul A. N. P. M., Meinsma R., Schmid V., Dobritzsch D., Hennekam R. C. M., Mannens M. M. A. M., Kiechle M., Etienne-Grimaldi M. C., Klümpen H. J., Maring J. G., Derleyn V. A., Maartense E., Milano G., Vijzelaar R., Gross E., Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Human Genetics 2010 128 5 529 538 2-s2.0-78049435885 10.1007/s00439-010-0879-3
117. Guo D. C., Gupta P., Tran-Fadulu V., Guidry T. V., Leduc M. S., Schaefer F. V., Milewicz D. M., An FBN1 pseudoexon mutation in a patient with Marfan syndrome: confirmation of cryptic mutations leading to disease. Journal of Human Genetics 2008 53 11-12 1007 1011 2-s2.0-57349109316 10.1007/s10038-008-0334-7
118. Metherell L. A., Akker S. A., Munroe P. B., Rose S. J., Caulfield M., Savage M. O., Chew S. L., Clark A. J. L., Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. American Journal of Human Genetics 2001 69 3 641 646 2-s2.0-0034892609 10.1086/323266 (Pubitemid 32777702)
119. Akker S. A., Misra S., Aslam S., Morgan E. L., Smith P. J., Khoo B., Chew S. L., Pre-spliceosomal binding of U1 small nuclear ribonucleoprotein (RNP) and heterogenous nuclear RNP E1 is associated with suppression of a growth hormone receptor pseudoexon. Molecular Endocrinology 2007 21 10 2529 2540 2-s2.0-34948821069 10.1210/me.2007-0038 (Pubitemid 47529363)
120. Vervoort R., Gitzelmann R., Lissens W., Liebaers I., A mutation (IVS8+0.6kbdelTC) creating a new donor splice site activates a cryptic exon in an Alu-element in intron 8 of the human β -glucuronidase gene. Human Genetics 1998 103 6 686 693 2-s2.0-0032406569 10.1007/s004390050892 (Pubitemid 29020765)
121. Purevsuren J., Fukao T., Hasegawa Y., Fukuda S., Kobayashi H., Yamaguchi S., Study of deep intronic sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency. Molecular Genetics and Metabolism 2008 95 1-2 46 51 2-s2.0-51649103469 10.1016/j.ymgme.2008.06.013
122. Sévenet N., Lellouch-Tubiana A., Schofield D., Hoang-Xuan K., Gessler M., Birnbaum D., Jeanpierre C., Jouvet A., Delattre O., Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Human Molecular Genetics 1999 8 13 2359 2368 2-s2.0-0345581429
123. Olsson A., Lind L., Thornell L. E., Holmberg M., Myopathy with lactic acidosis is linked to chromosome 12q23.3-24.11 and caused by an intron mutation in the ISCU gene resulting in a splicing defect. Human Molecular Genetics 2008 17 11 1666 1672 2-s2.0-44349149346 10.1093/hmg/ddn057 (Pubitemid 351737170)
124. Mochel F., Knight M. A., Tong W. H., Hernandez D., Ayyad K., Taivassalo T., Andersen P. M., Singleton A., Rouault T. A., Fischbeck K. H., Haller R. G., Splice mutation in the Iron-Sulfur cluster scaffold protein ISCU causes myopathy with exercise intolerance. American Journal of Human Genetics 2008 82 3 652 660 2-s2.0-41149169596 10.1016/j.ajhg.2007.12.012
125. Kollberg G., Tulinius M., Melberg A., Darin N., Andersen O., Holmgren D., Oldfors A., Holme E., Clinical manifestation and a new ISCU mutation in ironsulphur cluster deficiency myopathy. Brain 2009 132 8 2170 2179 2-s2.0-67749084367 10.1093/brain/awp152
126. Lucien N., Chiaroni J., Cartron J. P., Bailly P., Partial deletion in the JK locus causing a JK(null) phenotype. Blood 2002 99 3 1079 1081 2-s2.0-0036464690 10.1182/blood.V99.3.1079 (Pubitemid 34525574)
127. Stucki M., Suormala T., Fowler B., Valle D., Baumgartner M. R., Cryptic exon activation by disruption of exon splice enhancer: a novel mechanism causing 3-methyl crotonyl-CoA carboxylase deficiency. The Journal of Biological Chemistry 2009 284 42 28953 28957 2-s2.0-70350357218 10.1074/jbc.M109.050674
128. Yamaguchi H., Fujimoto T., Nakamura S., Ohmura K., Mimori T., Matsuda F., Nagata S., Aberrant splicing of the milk fat globule-EGF factor 8 (MFG-E8) gene in human systemic lupus erythematosus. European Journal of Immunology 2010 40 6 1778 1785 2-s2.0-77953312484 10.1002/eji.200940096
129. Mancini C., Vaula G., Scalzitti L., Cavalieri S., Bertini E., Aiello C., Lucchini C., Gatti R. A., Brussino A., Brusco A., Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1) due to a homozygous deep intronic splicing mutation (c.895-226T>G) abrogated in vitro using an antisense morpholino oligonucleotide. Neurogenetics 2012 13 3 205 214 2-s2.0-84860563545 10.1007/s10048-012-0331-z
130. Homolova K., Zavadakova P., Doktor T. K., Schroeder L. D., Kozich V., Andresen B. S., The deep intronic c.903+469T > C mutation in the MTRR gene creates an SF2/ASF binding exonic splicing enhancer, which leads to pseudoexon activation and causes the cblE type of homocystinuria. Human Mutation 2010 31 4 437 444 2-s2.0-77950450545 10.1002/humu.21206
131. Vetrini F., Tammaro R., Bondanza S., Surace E. M., Auricchio A., de Luca M., Ballabio A., Marigo V., Aberrant splicing in the ocular albinism type 1 gene (OA1/GPR143) is corrected in vitro by morpholino antisense oligonucleotides. Human Mutation 2006 27 5 420 426 2-s2.0-33646359203 10.1002/humu.20303 (Pubitemid 43673328)
132. Mitchell G. A., Labuda D., Fontaine G., Saudubray J. M., Bonnefont J. P., Lyonnet S., Brody L. C., Steel G., Obie C., Valle D., Splice-mediated insertion of an Alu sequence inactivates ornithine δ -aminotransferase: a role for Alu elements in human mutation. Proceedings of the National Academy of Sciences of the United States of America 1991 88 3 815 819 2-s2.0-0026082569 10.1073/pnas.88.3.815 (Pubitemid 21916114)
133. Webb T. R., Parfitt D. A., Gardner J. C., Martinez A., Bevilacqua D., Davidson A. E., Zito I., Thiselton D. L., Ressa J. H., Apergi M., Schwarz N., Kanuga N., Michaelides M., Cheetham M. E., Gorin M. B., Hardcastle A. J., Deep intronic mutation in OFD1, identified by targeted genomic next-generation sequencing, causes a severe form of X-linked retinitis pigmentosa (RP23). Human Molecular Genetics 2012 21 3647 3654
134. Ogino W., Takeshima Y., Nishiyama A., Okizuka Y. O., Yagi M., Tsuneishi S., Saiki K., Kugo M., Matsuo M., Mutation analysis of the ornithine transcarbamylase (OTC) gene in five Japanese OTC deficiency patients revealed two known and three novel mutations including a deep intronic mutation. Kobe Journal of Medical Sciences 2007 53 5 229 240 2-s2.0-39649093668 (Pubitemid 351286235)
135. Rincón A., Aguado C., Desviat L. R., Sánchez-Alcudia R., Ugarte M., Pérez B., Propionic and methylmalonic acidemia: antisense therapeutics for intronic variations causing aberrantly spliced messenger RNA. American Journal of Human Genetics 2007 81 6 1262 1270 2-s2.0-36749049831 10.1086/522376 (Pubitemid 350211454)
136. Christie P. T., Harding B., Nesbit M. A., Whyte M. P., Thakker R. V., X-linked hypophosphatemia attributable to pseudoexons of the PHEX gene. Journal of Clinical Endocrinology and Metabolism 2001 86 8 3840 3844 2-s2.0-0034891901 10.1210/jc.86.8.3840 (Pubitemid 32755986)
137. Michel-Calemard L., Dijoud F., Till M., Lambert J. C., Vercherat M., Tardy V., Coubes C., Morel Y., Pseudoexon activation in the PKHD1 gene: a French founder intronic mutation IVS46+653A>G causing severe autosomal recessive polycystic kidney disease. Clinical Genetics 2009 75 2 203 206 2-s2.0-58849085105 10.1111/j.1399-0004.2008.01106.x
138. Vega A. I., Perez-Cerda C., Desviat L. R., Matthijs G., Ugarte M., Pérez B., Functional analysis of three splicing mutations identified in the PMM2 gene: toward a new therapy for congenital disorder of glycosylation type IA. Human Mutation 2009 30 5 795 803 2-s2.0-66749140994 10.1002/humu.20960
139. Schollen E., Keldermans L., Foulquier F., Briones P., Chabas A., Sánchez-Valverde F., Adamowicz M., Pronicka E., Wevers R., Matthijs G., Characterization of two unusual truncating PMM2 mutations in two CDG-Ia patients. Molecular Genetics and Metabolism 2007 90 4 408 413 2-s2.0-33947573898 10.1016/j.ymgme.2007.01.003 (Pubitemid 46484434)
140. Frio T. R., McGee T. L., Wade N. M., Iseli C., Beckmann J. S., Berson E. L., Rivolta C., A single-base substitution within an intronic repetitive element causes dominant retinitis pigmentosa with reduced penetrance. Human Mutation 2009 30 9 1340 1347 2-s2.0-69649087772 10.1002/humu.21071
141. Liu H. C., Eng H. L., Yang Y. F., Wang Y. H., Lin K. T., Wu H. L., Lin T. M., Aberrant RNA splicing in RHD 7-9 exons of DEL individuals in Taiwan: A Mechanism Study. Biochimica et Biophysica Acta 2010 1800 6 565 573 2-s2.0-77952312473 10.1016/j.bbagen.2010.02.006
142. Monnier N., Ferreiro A., Marty I., Labarre-Villa A., Mezin P., Lunardi J., A homozygous splicing mutation causing a depletion of skeletal muscle RYR1 is associated with multi-minicore disease congenital myopathy with ophthalmoplegia. Human Molecular Genetics 2003 12 10 1171 1178 2-s2.0-0038101427 10.1093/hmg/ddg121 (Pubitemid 36622149)
143. Nozu K., Iijima K., Nozu Y., Ikegami E. I., Imai T., Fu X. J., Kaito H., Nakanishi K., Yoshikawa N., Matsuo M., A deep intronic mutation in the SLC12A3 gene leads to gitelman syndrome. Pediatric Research 2009 66 5 590 593 2-s2.0-73249119328 10.1203/PDR.0b013e3181b9b4d3
144. Vaché C., Besnard T., le Berre P., García-García G., Baux D., Larrieu L., Abadie C., Blanchet C., Bolz H. J., Millan J., Hamel C., Malcolm S., Claustres M., Roux A. F., Usher syndrome type 2 caused by activation of an USH2A pseudoexon: implications for diagnosis and therapy. Human Mutation 2012 33 1 104 108 2-s2.0-84857691632 10.1002/humu.21634
145. Ruoslahti E., Fibronectin and its receptors. Annual Review of Biochemistry 1988 57 375 413 2-s2.0-0023920076
146. White E. S., Baralle F. E., Muro A. F., New insights into form and function of fibronectin splice variants. Journal of Pathology 2008 216 1 1 14 2-s2.0-50249176028 10.1002/path.2388
147. Vibe-Pedersen K., Magnusson S., Baralle F. E., Donor and acceptor splice signals within an exon of the human fibronectin gene: a new type of differential splicing. FEBS Letters 1986 207 2 287 291 2-s2.0-0023032992 (Pubitemid 17176193)
148. Hershberger R. P., Culp L. A., Cell-type-specific expression of alternatively spliced human fibronectin IIICS mRNAs. Molecular and Cellular Biology 1990 10 2 662 671 2-s2.0-0025138983
149. Mould A. P., Humphries M. J., Identification of a novel recognition sequence for the integrin α 4 β 1 in the COOH-terminal heparin-binding domain of fibronectin. The EMBO Journal 1991 10 13 4089 4095 2-s2.0-0025932687 (Pubitemid 21905439)
150. Humphries M. J., Komoriya A., Akiyama S. K., Identification of two distinct regions of the type III connecting segment of human plasma fibronectin that promote cell type-specific adhesion. The Journal of Biological Chemistry 1987 262 14 6886 6892 2-s2.0-0023223464 (Pubitemid 17104150)
151. Mould A. P., Askari J. A., Craig S. E., Garratt A. N., Clements J., Humphries M. J., Integrin α 4 β 1-mediated melanoma cell adhesion and migration on vascular cell adhesion molecule-1 (VCAM-1) and the alternatively spliced IIICS region of fibronectin. The Journal of Biological Chemistry 1994 269 44 27224 27230 2-s2.0-0028172398
152. Kumazaki T., Mitsui Y., Hamada K., Sumida H., Nishiyama M., Detection of alternative splicing of fibronectin mRNA in a single cell. Journal of Cell Science 1999 112, part 10 10 1449 1453 2-s2.0-0033014330 (Pubitemid 29261307)
153. Schofield K. P., Humphries M. J., Identification of fibronectin IIICS variants in human bone marrow stroma. Blood 1999 93 1 410 411 2-s2.0-0032910347 (Pubitemid 29019430)
154. Trefzer U., Chen Y., Herberth G., Hofmann M. A., Kiecker F., Guo Y., Sterry W., The monoclonal antibody SM5-1 recognizes a fibronectin variant which is widely expressed in melanoma. BMC Cancer 2006 6, article 8 2-s2.0-32044469141 10.1186/1471-2407-6-8 (Pubitemid 43193493)
155. Mardon H. J., Sebastio G., Regulation of alternative splicing in the IIICS region of human fibronectin pre-mRNA encoding cell binding sites CS1 and CS5. Journal of Cell Science 1992 103, part 2 2 423 433 2-s2.0-0026492095
156. Silman I., Sussman J. L., Acetylcholinesterase: "Classical" and "non-classical" functions and pharmacology. Current Opinion in Pharmacology 2005 5 3 293 302 2-s2.0-18744414554 10.1016/j.coph.2005.01.014 (Pubitemid 40674253)
157. Soreq H., Seidman S., Acetylcholinesterase-new roles for an old actor. Nature Reviews Neuroscience 2001 2 4 294 302 2-s2.0-0035320772 10.1038/35067589 (Pubitemid 33673070)
158. Massoulié J., The origin of the molecular diversity and functional anchoring of cholinesterases. NeuroSignals 2002 11 3 130 143 2-s2.0-0036560908 10.1159/000065054 (Pubitemid 37490494)
159. Chan R. Y. Y., Adatia F. A., Krupa A. M., Jasmin B. J., Increased expression of acetylcholinesterase T and R transcripts during hematopoietic differentiation is accompanied by parallel elevations in the levels of their respective molecular forms. The Journal of Biological Chemistry 1998 273 16 9727 9733 2-s2.0-0032540337 10.1074/jbc.273.16.9727 (Pubitemid 28183064)
160. Perrier N. A., Salani M., Falasca C., Bon S., Augusti-Tocco G., Massoulié J., The readthrough variant of acetylcholinesterase remains very minor after heat shock, organophosphate inhibition and stress, in cell culture and in vivo. Journal of Neurochemistry 2005 94 3 629 638 2-s2.0-23244463063 10.1111/j.1471-4159.2005.03140.x (Pubitemid 41098495)
161. Grisaru D., Sternfeld M., Eldor A., Glick D., Soreq H., Structural roles of acetylcholinesterase variants in biology and pathology. European Journal of Biochemistry 1999 264 3 672 686 2-s2.0-0033568704 10.1046/j.1432-1327.1999. 00693.x (Pubitemid 29437196)
162. Meshorer E., Soreq H., Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends in Neurosciences 2006 29 4 216 224 2-s2.0-33645988822 10.1016/j.tins.2006.02.005
163. Perry C., Sklan E. H., Birikh K., Shapira M., Trejo L., Eldor A., Soreq H., Complex regulation of acetylcholinesterase gene expression in human brain tumors. Oncogene 2002 21 55 8428 8441 2-s2.0-0037028246 10.1038/sj.onc.1205945 (Pubitemid 36054884)
164. Perry C., Sklan E. H., Soreq H., CREB regulates AChE-R-induced proliferation of human glioblastoma cells. Neoplasia 2004 6 3 279 286 2-s2.0-2442666424 (Pubitemid 38657084)
165. Mor I., Bruck T., Greenberg D., Berson A., Schreiber L., Grisaru D., Soreq H., Alternate AChE-R variants facilitate cellular metabolic activity and resistance to genotoxic stress through enolase and RACK1 interactions. Chemico-Biological Interactions 2008 175 1-3 11 21 2-s2.0-50649085694 10.1016/j.cbi.2008.05.019
166. Montenegro M. F., Ruiz-Espejo F., Campoy F. J., Muñoz-Delgado E., De La Cadena M. P., Rodríguez-Berrocal F. J., Vidal C. J., Cholinesterases are down-expressed in human colorectal carcinoma. Cellular and Molecular Life Sciences 2006 63 18 2175 2182 2-s2.0-33749076488 10.1007/s00018-006-6231-3 (Pubitemid 44465690)
167. Li B., Pan H., Winkelmann J. C., Dai W., Thrombopoietin and its alternatively spliced form are expressed in human amygdala and hippocampus. Blood 1996 87 12 5382 5384 2-s2.0-0030001443 (Pubitemid 26189883)
168. Sungaran R., Markovic B., Chong B. H., Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997 89 1 101 107 2-s2.0-0031035555 (Pubitemid 26428183)
169. Dame C., Wolber E. M., Freitag P., Hofmann D., Bartmann P., Fandrey J., Thrombopoietin gene expression in the developing human central nervous system. Developmental Brain Research 2003 143 2 217 223 2-s2.0-0037487003 10.1016/S0165-3806(03)00134-2 (Pubitemid 36835864)
170. Marcucci R., Romano M., Thrombopoietin and its splicing variants: structure and functions in thrombopoiesis and beyond. Biochimica et Biophysica Acta 2008 1782 7-8 427 432 2-s2.0-49649099786 10.1016/j.bbadis.2008.03.007
171. Romano M., Marcucci R., Baralle F. E., Splicing of constitutive upstream introns is essential for the recognition of intra-exonic suboptimal splice sites in the thrombopoietin gene. Nucleic Acids Research 2001 29 4 886 894 2-s2.0-0035865835 (Pubitemid 32162256)
172. Wada T., Nagata Y., Nagahisa H., Okutomi K., Ha S. H., Ohnuki T., Kanaya T., Matsumura M., Todokoro K., Characterization of the truncated thrombopoietin variants. Biochemical and Biophysical Research Communications 1995 213 3 1091 1098 2-s2.0-0029086661 10.1006/bbrc.1995.2239
173. Hoffman R. C., Andersen H., Walker K., Krakover J. D., Patel S., Stamm M. R., Osborn S. G., Peptide, disulfide, and glycosylation mapping of recombinant human thrombopoietin from Ser1 to Arg246. Biochemistry 1996 35 47 14849 14861 2-s2.0-0030461838 10.1021/bi961075b (Pubitemid 26423819)
174. Wu X. L., Nakayama M., Adamson J. W., Identification of five new isoforms of murine thrombopoietin mRNA. Biochemical and Biophysical Research Communications 2000 276 1 137 143 2-s2.0-0034675274 10.1006/bbrc.2000.3428
175. Sasaki Y., Takahashi T., Miyazaki H., Matsumoto A., Kato T., Nakamura K., Iho S., Okuno Y., Nakao K., Production of thrombopoietin by human carcinomas and its novel isoforms. Blood 1999 94 6 1952 1960 2-s2.0-0033568423 (Pubitemid 29430411)
176. Bonnal S., Vigevani L., Valcarcel J., The spliceosome as a target of novel antitumour drugs. Nature Reviews Drug Discovery 2012 11 847 859
177. Zaharieva E., Chipman J. K., Soller M., Alternative splicing interference by xenobiotics. Toxicology 2012 296 1-3 1 12 2-s2.0-84860009905 10.1016/j.tox.2012.01.014
178. Muntoni F., Wood M. J. A., Targeting RNA to treat neuromuscular disease. Nature Reviews Drug Discovery 2011 10 8 621 637 2-s2.0-79960981599 10.1038/nrd3459
179. Kole R., Krainer A. R., Altman S., RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nature Reviews Drug Discovery 2012 11 2 125 140 2-s2.0-84856431819 10.1038/nrd3625
180. Aartsma-Rus A., Van Ommen G. J. B., Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007 13 10 1609 1624 2-s2.0-34748906143 10.1261/rna.653607 (Pubitemid 47481669)
181. Dominski Z., Kole R., Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proceedings of the National Academy of Sciences of the United States of America 1993 90 18 8673 8677 2-s2.0-0027284424 (Pubitemid 23277732)
182. Kishore S., Stamm S., The snoRNA HBII-52 regulates alternative splicing of the serotonin receptor 2C. Science 2006 311 5758 230 232 2-s2.0-30844442607 10.1126/science.1118265 (Pubitemid 43108188)
183. Aartsma-Rus A., van Vliet L., Hirschi M., Janson A. A. M., Heemskerk H., de Winter C. L., de Kimpe S., van Deutekom J. C. T., 't Hoen P. A. C., van Ommen G. J. B., Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Molecular Therapy 2009 17 3 548 553 2-s2.0-61649127296 10.1038/mt.2008.205
184. Heemskerk H., De Winter C. L., Van Ommen G. J. B., Van Deutekom J. C. T., Aartsma-Rus A., Development of antisense-mediated exon skipping as a treatment for Duchenne muscular dystrophy. Annals of the New York Academy of Sciences 2009 1175 71 79 2-s2.0-70349451258 10.1111/j.1749-6632.2009.04973.x
185. Kendall G. C., Mokhonova E. I., Moran M., Sejbuk N. E., Wang D. W., Silva O., Wang R. T., Martinez L., Lu Q. L., Damoiseaux R., Spencer M. J., Nelson S. F., Miceli M. C., Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy. Science Translational Medicine 2012 4 164, article 164ra160 10.1126/scitranslmed.3005054
186. Gendron D., Carriero S., Garneau D., Villemaire J., Klinck R., Elela S. A., Damha M. J., Chabot B., Modulation of 5′ splice site selection using tailed oligonucleotides carrying splicing signals. BMC Biotechnology 2006 6, article 5 2-s2.0-33644543767 10.1186/1472-6750-6-5
187. Garcia-Blanco M. A., Baraniak A. P., Lasda E. L., Alternative splicing in disease and therapy. Nature Biotechnology 2004 22 5 535 546 2-s2.0-2342450548 10.1038/nbt964 (Pubitemid 38585905)
188. Nissim-Rafinia M., Aviram M., Randell S. H., Shushi L., Ozeri E., Chiba-Falek O., Eidelman O., Pollard H. B., Yankaskas J. R., Kerem B., Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Reports 2004 5 11 1071 1077 2-s2.0-10044270719 10.1038/sj.embor.7400273 (Pubitemid 39600206)
189. Pros E., Fernández-Rodríguez J., Benito L., Ravella A., Capellá G., Blanco I., Serra E., Lázaro C., Modulation of aberrant NF1 pre-mRNA splicing by kinetin treatment. European Journal of Human Genetics 2010 18 5 614 617 2-s2.0-77951623402 10.1038/ejhg.2009.212
190. Cermak T., Doyle E. L., Christian M., Wang L., Zhang Y., Schmidt C., Baller J. A., Somia N. V., Bogdanove A. J., Voytas D. F., Efficient design and assembly of custom TALEN and other TAL effector-based constructs for DNA targeting. Nucleic Acids Research 2011 39 12, article e82 10.1093/nar/gkr218